441 related articles for article (PubMed ID: 29746229)
41. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer.
Peng YF; Imano M; Itoh T; Satoh T; Chiba Y; Imamoto H; Tsubaki M; Nishida S; Yasuda T; Furukawa H
J Surg Oncol; 2015 Jun; 111(8):1041-6. PubMed ID: 26060133
[TBL] [Abstract][Full Text] [Related]
42. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Tamura S; Miki H; Okada K; Miyake T; Yoshimura M; Suzuki R; Nakahira S; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Int J Clin Oncol; 2008 Dec; 13(6):536-40. PubMed ID: 19093182
[TBL] [Abstract][Full Text] [Related]
43. [A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Iwai N; Wakabayashi N; Matsumoto N; Morita Y; Tanaka N; Yoriki H; Fujii K; Takada R; Takaya H; Masuzawa A; Takami S; Kataoka K
Gan To Kagaku Ryoho; 2015 Mar; 42(3):351-4. PubMed ID: 25812506
[TBL] [Abstract][Full Text] [Related]
44. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Satoi S; Fujii T; Yanagimoto H; Motoi F; Kurata M; Takahara N; Yamada S; Yamamoto T; Mizuma M; Honda G; Isayama H; Unno M; Kodera Y; Ishigami H; Kon M
Ann Surg; 2017 Feb; 265(2):397-401. PubMed ID: 28059968
[TBL] [Abstract][Full Text] [Related]
45. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Nakanishi K; Kobayashi D; Mochizuki Y; Ishigure K; Ito S; Kojima H; Ishiyama A; Fujitake S; Shikano T; Morita S; Kodera Y
Int J Clin Oncol; 2016 Jun; 21(3):557-65. PubMed ID: 26547424
[TBL] [Abstract][Full Text] [Related]
46. Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.
Deng T; Xu N; Xiong JP; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Huang DZ; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
J Chemother; 2013 Feb; 25(1):56-9. PubMed ID: 23433446
[TBL] [Abstract][Full Text] [Related]
47. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
48. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
[TBL] [Abstract][Full Text] [Related]
49. [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
Asami S; Idani H; Kubo S; Sasaki H; Kurose Y; Nojima H; Yoshioka T; Muro M; Kumano K; Hirata M; Yamashita T; Kin H; Takakura N
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2287-9. PubMed ID: 20037398
[TBL] [Abstract][Full Text] [Related]
50. [Chemotherapeutic Strategies for Peritoneal Dissemination of Gastric Cancer].
Matsushima T; Wakatsuki T; Takahari D; Chin K; Yamaguchi K
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2477-2480. PubMed ID: 28028252
[TBL] [Abstract][Full Text] [Related]
51. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
Yoshikawa T; Morita S; Tanabe K; Nishikawa K; Ito Y; Matsui T; Fujitani K; Kimura Y; Fujita J; Aoyama T; Hayashi T; Cho H; Tsuburaya A; Miyashita Y; Sakamoto J
Eur J Cancer; 2016 Jul; 62():103-11. PubMed ID: 27244537
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.
Matsuda S; Takahashi T; Fukada J; Fukuda K; Kawakubo H; Saikawa Y; Kawaguchi O; Takeuchi H; Shigematsu N; Kitagawa Y
Radiat Oncol; 2014 Jan; 9():9. PubMed ID: 24398302
[TBL] [Abstract][Full Text] [Related]
53. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
Lee KW; Chung IJ; Ryu MH; Park YI; Nam BH; Oh HS; Lee KH; Han HS; Seo BG; Jo JC; Lee HR; Kim JW; Park SR; Cho SH; Kang YK;
Gastric Cancer; 2021 Jan; 24(1):156-167. PubMed ID: 32596783
[TBL] [Abstract][Full Text] [Related]
54. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Kitayama J; Ishigami H; Kaisaki S; Hidemura A; Kato M; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Nagawa H
Oncology; 2010; 78(1):40-6. PubMed ID: 20197706
[TBL] [Abstract][Full Text] [Related]
55. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Kaira K; Imai H; Souma R; Sakurai R; Miura Y; Sunaga N; Kasahara N; Tsukagoshi Y; Koga Y; Kitahara S; Kotake M; Minato K; Naruse I; Fukushima Y; Hisada T; Ishizuka T
Anticancer Res; 2019 May; 39(5):2483-2491. PubMed ID: 31092443
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Yamaguchi T; Takashima A; Nagashima K; Makuuchi R; Aizawa M; Ohashi M; Tashiro K; Yamada T; Kinoshita T; Hata H; Kawachi Y; Kawabata R; Tsuji T; Hihara J; Sakamoto T; Fukagawa T; Katai H; Higuchi K; Boku N
Ann Surg Oncol; 2020 Jan; 27(1):284-292. PubMed ID: 31535301
[TBL] [Abstract][Full Text] [Related]
57. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
58. A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Moriwaki T; Hirai S; Hironaka S; Amagai K; Soeda A; Sato M; Nihei T; Hirose M; Matsuda K; Ohkawara A; Yamaguchi T; Ozeki M; Mamiya T; Murashita T; Hyodo I
Gastric Cancer; 2014 Apr; 17(2):354-61. PubMed ID: 23852397
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
